Notably, no evidence was found to suggest that lipid traits have a causal association with IPF risk, which implies that the mechanism by which PCSK9 inhibitors influence IPF risk may be distinct from its effects on lipid metabolism. This evidence concerns the gene PCSK9 and idiopathic pulmonary fibrosis.